A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors

Part of paid clinical trials in Sarasota, Florida.

Sponsor
Janssen Research & Development, LLC
Study ID
NCT07107230
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • JNJ-95437446 — DRUG
    JNJ-95437446 will be administered.

Study Details

The purpose of this study is to determine recommended phase 2 doses (RP2Ds) of JNJ-95437446 in Part 1, and to further evaluate the safety of the RP2Ds in participants with advanced solid tumors in Part 2.

Key Dates

Start date
Jul 15, 2025
Status verified
Jun 2026
Primary completion
Nov 18, 2027
Completion
Apr 24, 2028

Study Design

Enrollment
380 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: JNJ-95437446
    Participants will receive JNJ-95437446 in Part 1 until at least two recommended phase 2 doses (RP2Ds) has been developed. Participants in Part 2 will receive JNJ-95437446 at the RP2Ds developed in Part 1.

Primary Outcome Measure

Number of Participants with Adverse Events (AEs) by Severity [ Time Frame: Up to 2 years and 4 months ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Florida Cancer SpecialistsSarasotaFlorida34232-
Tennessee OncologyNashvilleTennessee37203-
NEXT OncologyFairfaxVirginia22031-

Find similar trials in Sarasota, FL

By condition
Colorectal cancer
By specialty
OncologyGI oncology
By research site
Florida Cancer Specialists· Sarasota, FLTennessee Oncology· Nashville, TNNEXT Oncology· Fairfax, VA

Related Studies